Carbapenem‐resistant Enterobacteriaceae: biology, epidemiology, and management

  title={Carbapenem‐resistant Enterobacteriaceae: biology, epidemiology, and management},
  author={Elizabeth Temkin and Amos Adler and Anat Lerner and Yehuda Carmeli},
  journal={Annals of the New York Academy of Sciences},
Introduced in the 1980s, carbapenem antibiotics have served as the last line of defense against multidrug‐resistant Gram‐negative organisms. Over the last decade, carbapenem‐resistant Enterobacteriaceae (CRE) have emerged as a significant public health threat. This review summarizes the molecular genetics, natural history, and epidemiology of CRE and discusses approaches to prevention and treatment. 

The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

The evolution of CRE is discussed, with a focus on the epidemiology of the CPE pandemic; risk factors for colonization and infection with the most common transmissible CPE worldwide, Klebsiella pneumoniae carbapenemase-producing K. pneumoniae are reviewed; and strategies used to halt the striking spread of these deadly pathogens are presented.

Clinical epidemiology of carbapenem-resistant 1 Enterobacteriaceae : a systematic review and meta-analyses 2 3 4

Title and abstracts of all retrieved citations were screened independently by KL and AV and studies were excluded if patients with CRE infections were compared to patients who were colonized with CRE.

The Pros, Cons, and Unknowns of Search and Destroy for Carbapenem-Resistant Enterobacteriaceae

A functional infection prevention and control program is fundamental to any strategy that serves to address the spread of microbes within a healthcare facility.

Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae

A review of the performance characteristics of rapid genomic and phenotypic methods available to accelerate the identification of carbapenemase-producing CRE-infected patients and strategies for their optimal implementation are described.

Carbapenem-Resistant Enterobacteriaceae Infections in Children

This article provides a comprehensive review of what is known to date about CRE, including clinical and molecular epidemiology, microbiologic diagnosis, antibiotic treatment options, and outcomes, and focuses on the available data on CRE in the pediatric population.

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

This article provides a comprehensive review of currently available treatment options for infections due to carbapenem-resistant enterobacteriaceae (CRE).

Carbapenem resistance in a rural part of southern India: Escherichia coli versus Klebsiella spp.

Assessment of the occurrence of CRE in a rural part of Tamil Nadu, south India found no valid data on the prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in India.

Multidrug-Resistant Gram-Negative Bacilli: Infection Prevention Considerations

This chapter will review the utility of various infection control measures in containing the spread of multidrug-resistant Gram-negative bacilli.

Spread of Carbapenem-Resistant Enterobacteriaceae in a Region, China: How to Control?

The frequent transfers of CRE patients between intra- and inter-hospitals were the main driving factors for the CRE increase and evidence-based measures could effectively reduce the prevalence but failed to control the dissemination of ST11-wzi141 KP clone.



Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae

Purpose of reviewRates of carbapenem-resistant Enterobacteriaceae (CRE), especially Klebsiella pneumoniae carbapenemase (KPC)-producing Gram-negatives, have increased worldwide. Infections caused by

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

The current epidemiology of CRE in the United States is described, including New Delhi metallo-β-lactamase, which highlights important prevention strategies.

Emerging carbapenemases: a global perspective.

  • T. Walsh
  • Biology
    International journal of antimicrobial agents
  • 2010

Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art

Current microbiological and clinical evidences supporting combination therapy for CR-KP infections are revised to address some of the issues.

Detection of OXA-48 Carbapenemase in the Pandemic Clone Escherichia coli O25b:H4-ST131 in the Course of Investigation of an Outbreak of OXA-48-Producing Klebsiella pneumoniae

Reports of carbapenemase producing Enterobacteriaceae (CPE) have increased dramatically in the past decade, and the number of cases is likely to have increased as a result.

Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-β-Lactamase Encoded by a Conjugative Plasmid

Enterobacteria appear to increasingly contribute to the spread of VIM-type enzymes as resistance to carbapenems is an emerging problem among gram-negative hospital pathogens.

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

This work evaluated the efficacy of a combination of ertapenem and doripenem in both an in vitro chemostat and an in vivo murine thigh infection model and demonstrated enhanced efficacy over either agent alone.

Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices

The aim of this review is to summarize the currently available laboratory methods and infection control options in carbapenem-resistant Enterobacteriaceae.

Carbapenem-Resistant KPC-2-Producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008

All of the carbapenem-resistant Escherichia coli (CREC) isolates identified in the authors' hospital from 2005 to 2008 were studied, and all carried blaKPC-2, and six of them were also extended-spectrum beta-lactamase producers.